Z

Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267

Watchlist Manager
Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267
Watchlist
Price: 10.6 CNY -0.38% Market Closed
Market Cap: 12.7B CNY

Relative Value

The Relative Value of one Zhejiang Hisun Pharmaceutical Co Ltd stock under the Base Case scenario is 16.32 CNY. Compared to the current market price of 10.6 CNY, Zhejiang Hisun Pharmaceutical Co Ltd is Undervalued by 35%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
16.32 CNY
Undervaluation 35%
Relative Value
Price
Z
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
26
vs Industry
69
Median 3Y
1.1
Median 5Y
1.1
Industry
2.6
Forward
1.3
vs History
50
vs Industry
31
Median 3Y
20.2
Median 5Y
23.8
Industry
21.7
Forward
25.6
vs History
77
vs Industry
45
Median 3Y
6
Median 5Y
6.2
Industry
16.6
vs History
20
vs Industry
32
Median 3Y
7.3
Median 5Y
6.5
Industry
22.5
vs History
55
vs Industry
54
Median 3Y
1.4
Median 5Y
1.6
Industry
2.3
vs History
36
vs Industry
61
Median 3Y
1.3
Median 5Y
1.5
Industry
2.9
Forward
1.5
vs History
60
vs Industry
52
Median 3Y
3.3
Median 5Y
3.5
Industry
5.5
vs History
69
vs Industry
1
Median 3Y
17
Median 5Y
17.9
Industry
13.1
Forward
9.3
vs History
69
vs Industry
1
Median 3Y
17
Median 5Y
17.9
Industry
16.6
Forward
21.6
vs History
80
vs Industry
42
Median 3Y
7.9
Median 5Y
8.4
Industry
15.8
vs History
80
vs Industry
33
Median 3Y
8.9
Median 5Y
11.4
Industry
19.1
vs History
46
vs Industry
60
Median 3Y
1
Median 5Y
1.1
Industry
1.9

Multiples Across Competitors

Competitors Multiples
Zhejiang Hisun Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267
12.7B CNY 1.3 23.2 16.4 16.4
US
Eli Lilly and Co
NYSE:LLY
955.6B USD 16.1 51.9 34.9 37.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
485.9B USD 5.3 19.3 15.8 20.5
CH
Roche Holding AG
SIX:ROG
247.6B CHF 4 26.3 11.3 13.1
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.8 29.9 108.2 158.4
CH
Novartis AG
SIX:NOVN
205.5B CHF 4.6 17.7 11.3 14.6
US
Merck & Co Inc
NYSE:MRK
248B USD 3.9 13 9.3 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.2 9.3 10.8
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
148B USD 2.4 15.1 7.6 10.4
P/E Multiple
Earnings Growth PEG
CN
Z
Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267
Average P/E: 23.3
23.2
-3%
N/A
US
Eli Lilly and Co
NYSE:LLY
51.9
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.3
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.9
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
13
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.1
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Z
Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267
Average EV/EBITDA: 399.2
16.4
23%
0.7
US
Eli Lilly and Co
NYSE:LLY
34.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.8
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.3
4%
2.8
UK
AstraZeneca PLC
LSE:AZN
108.2
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Z
Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267
Average EV/EBIT: 1 709.1
16.4
-4%
N/A
US
Eli Lilly and Co
NYSE:LLY
37.4
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.1
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
158.4
23%
6.9
CH
Novartis AG
SIX:NOVN
14.6
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
8%
1.3